Correlation Between Galera Therapeutics and Scopus Biopharma
Can any of the company-specific risk be diversified away by investing in both Galera Therapeutics and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Galera Therapeutics and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Galera Therapeutics and Scopus Biopharma, you can compare the effects of market volatilities on Galera Therapeutics and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Galera Therapeutics with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Galera Therapeutics and Scopus Biopharma.
Diversification Opportunities for Galera Therapeutics and Scopus Biopharma
0.43 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Galera and Scopus is 0.43. Overlapping area represents the amount of risk that can be diversified away by holding Galera Therapeutics and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Galera Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Galera Therapeutics are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Galera Therapeutics i.e., Galera Therapeutics and Scopus Biopharma go up and down completely randomly.
Pair Corralation between Galera Therapeutics and Scopus Biopharma
If you would invest 10.00 in Scopus Biopharma on September 5, 2024 and sell it today you would earn a total of 0.00 from holding Scopus Biopharma or generate 0.0% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Galera Therapeutics vs. Scopus Biopharma
Performance |
| Timeline |
| Galera Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
| Scopus Biopharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Galera Therapeutics and Scopus Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Galera Therapeutics and Scopus Biopharma
The main advantage of trading using opposite Galera Therapeutics and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Galera Therapeutics position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.| Galera Therapeutics vs. Mereo BioPharma Group | Galera Therapeutics vs. Terns Pharmaceuticals | Galera Therapeutics vs. PDS Biotechnology Corp | Galera Therapeutics vs. Inozyme Pharma |
| Scopus Biopharma vs. Scpharmaceuticals | Scopus Biopharma vs. DiaMedica Therapeutics | Scopus Biopharma vs. Monopar Therapeutics | Scopus Biopharma vs. Pasithea Therapeutics Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Complementary Tools
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |